Dr. Antonio Calles 🫁🚭(@Tony_Calles) 's Twitter Profileg
Dr. Antonio Calles 🫁🚭

@Tony_Calles

Medical Oncology 🏥 Hospital General Universitario Gregorio Marañón⎪@myESMO Faculty 🫁 ⎪Power to the patients #endlungcancer #lcsm

ID:2155543177

linkhttp://www.linkedin.com/in/antonio-calles-001 calendar_today25-10-2013 19:57:31

22,2K Tweets

10,6K Followers

4,6K Following

Dr. Antonio Calles 🫁🚭(@Tony_Calles) 's Twitter Profile Photo

Final Phase Ib TATTON: Osimertinib+ Savolitinib to Overcome Acquired MET-Mediated Resistance in EGFR Mutated MET-Amplified NSCLC. MET copy-number ≥10 and EGFRm circulating tumor DNA clearance predict better outcomes.
aacrjournals.org/cancerdiscover…

Final Phase Ib TATTON: Osimertinib+ Savolitinib to Overcome Acquired MET-Mediated Resistance in EGFR Mutated MET-Amplified NSCLC. MET copy-number ≥10 and EGFRm circulating tumor DNA clearance predict better outcomes. #LCSM aacrjournals.org/cancerdiscover…
account_circle
Tertulias Oncológicas(@TOncologicas) 's Twitter Profile Photo

Ya hemos empezado la VI Edición de la Jornada Anual de Tertulias Oncológicas con la mesa plenaria sobre 'Medicina personalizada vs immunoterapia'.
Dr. Antonio Calles 🫁🚭 Elena Elez Luis Paz-Ares

Ya hemos empezado la VI Edición de la Jornada Anual de Tertulias Oncológicas con la mesa plenaria sobre 'Medicina personalizada vs immunoterapia'. @Tony_Calles @elena_elez @LuisPaz_Ares
account_circle
Sonia Cid(@soniacidc) 's Twitter Profile Photo

Excelente presentación sobre y grandes tertulianos en Tertulias Oncológicas aportando conocimiento. Gracias a todos por seguir estudiando y procurando que los vivamos más y mejor.

account_circle
Tertulias Oncológicas(@TOncologicas) 's Twitter Profile Photo

Empezando la ronda de preguntas de la mesa plenaria sobre 'Medicina personalizada vs immunoterapia' con
Elena Élez Elena Elez, Antonio Calles Dr. Antonio Calles 🫁🚭, Luis Paz-Ares Luis Paz-Ares, Josep M. Piulats y Miguel Fernández de Sanmamed.

Empezando la ronda de preguntas de la mesa plenaria sobre 'Medicina personalizada vs immunoterapia' con Elena Élez @elena_elez, Antonio Calles @Tony_Calles, Luis Paz-Ares @LuisPaz_Ares, Josep M. Piulats y Miguel Fernández de Sanmamed.
account_circle
Dr. Antonio Calles 🫁🚭(@Tony_Calles) 's Twitter Profile Photo

Practice informative: Risk of Radiation Pneumonitis in Patients Receiving Osimertinib and Thoracic Radiotherapy (N=41) G2+ in 19.5% (including 1 death), median onset 4.7 months (range: 3.1–6.9). Pneumonitis associated with increased lung V20 and V5. redjournal.org/article/S0360-…

account_circle
Dr. Antonio Calles 🫁🚭(@Tony_Calles) 's Twitter Profile Photo

Stage IV ALK+ Lung adenocarcinoma
1L Alectinib: PR lasting 16 months
2L Carbo-pem —> pemetrexed (on course #41): ongoing response +26 months.
cc: Syed Mohi Ahmed

Stage IV ALK+ Lung adenocarcinoma 1L Alectinib: PR lasting 16 months 2L Carbo-pem —> pemetrexed (on course #41): ongoing response +26 months. #lcsm cc: @SyedMAhmedMDPhD
account_circle
Dipesh Uprety MD FACP(@dipeshuprety4) 's Twitter Profile Photo

In this multi-center, retrospective study JTO & JTO CRR for uncommon EGFR mutation (n=60), osimertinib demonstrated an ORR of 61% (44% for denovo T790M, 47% for G719X ORR & 80% for L861Q) Md PFS 9.5 mo Md DOR 17.4 mo & Md OS of 24.5 mo OncoAlert
bit.ly/3gLOtFP

account_circle
Jarushka Naidoo(@DrJNaidoo) 's Twitter Profile Photo

Osimertinib in NSCLC w uncommon EGFR mutns JTO & JTO CRR:

- 60pt retrosp study, overall ORR 66%
- G719X ORR 47% mPFS 8.8m mDOR 9.1m
- L861Q ORR 80% mPFS 16m mDOR 16m
- de novo T790M ORR 44% mPFS 12.7m mDOR 46.2m

?⬇️ORR T790M than expected, important study

jto.org/article/S1556-…

account_circle